Amgen USA Inc — Federal Contractor Profile
AMGEN USA INC: $479.15B in Sole-Source Government Contracts
Contractor Overview
Total Contract Value: $479,149,809,580 ($479.1B)
Total Awards: 661
Company Profile
AMGEN USA INC is a biotechnology company that specializes in the development, manufacturing, and marketing of biologics for the treatment of serious diseases. Their core capabilities include research and development, manufacturing, and commercialization of innovative pharmaceutical products. AMGEN USA INC has a significant presence in government contracting, with a total contract value of $479.15 billion and 661 contracts. However, the company has not won any new contracts recently, and all of their contracts are sole-source, indicating a lack of competitive bidding. This sole-source pattern raises concerns about the transparency and fairness of the contracting process. AMGEN USA INC's top agency clients are not specified, but their dependency on a few key agencies could pose risks if those agencies reduce their spending or shift to more competitive bidding processes. The company's contract patterns reveal a strong focus on maintaining existing relationships rather than pursuing new opportunities, which could limit their growth potential. Compared to industry peers, AMGEN USA INC is a dominant player in the biotechnology sector, but their reliance on sole-source contracts and lack of competitive bidding could be seen as a competitive disadvantage.
Specializations
- Biologics development
- Pharmaceutical manufacturing
- Serious disease treatment
- Genetic research
- Clinical trials
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: N/A (no recent contracts available)
Sole Source Rate: 100%
Recompete Rate: N/A (no recent contracts available)
Competitive Position
AMGEN USA INC is a dominant player in the biotechnology sector, known for its innovative pharmaceutical products and strong research capabilities. However, their reliance on sole-source contracts and lack of competitive bidding could be seen as a competitive disadvantage. The company's focus on maintaining existing relationships rather than pursuing new opportunities could limit their growth potential.
Value to Taxpayers
AMGEN USA INC's sole-source contracts and lack of competitive bidding raise concerns about the transparency and fairness of the contracting process. While the company's innovative products and strong research capabilities are valuable, the lack of competitive bidding could lead to higher costs for taxpayers. The company's contract sizes are substantial, which could be a concern if the contracts are not providing good value for the money.
Agency Relationships
The specific agencies that rely most on AMGEN USA INC are not specified, but their dependency on a few key agencies could pose risks if those agencies reduce their spending or shift to more competitive bidding processes. This concentration of clients could lead to dependency risks and concentration concerns.
Red Flags
- 100% sole-source rate: This indicates a lack of competitive bidding, which could lead to higher costs for taxpayers.
- No recent contracts: This suggests that the company is not actively pursuing new opportunities, which could limit their growth potential.
- No competitive win rate: The company has not won any new contracts through competitive bidding, which could be a competitive disadvantage.
- No recompete/renewal rate: The lack of recent contracts and recompete/renewal data makes it difficult to assess the company's performance and growth trajectory.
Green Flags
- Innovative pharmaceutical products: AMGEN USA INC's innovative products and strong research capabilities are valuable to the government and taxpayers.
- Strong research capabilities: The company's focus on research and development is a positive indicator of their commitment to innovation.
- Substantial contract sizes: The company's large contract sizes indicate their importance to the government and the value of their products.
Key Contracts
AMGEN USA INC's most significant contracts are likely to be related to the development, manufacturing, and distribution of biologics for the treatment of serious diseases. These contracts are likely to be sole-source, indicating a lack of competitive bidding. The company's focus on maintaining existing relationships rather than pursuing new opportunities could limit their growth potential. The contracts reveal that AMGEN USA INC is a dominant player in the biotechnology sector, but their reliance on sole-source contracts and lack of competitive bidding could be seen as a competitive disadvantage. The company's track record, notable projects, and performance history are not specified, but their contract patterns reveal a strong focus on maintaining existing relationships rather than pursuing new opportunities.
Frequently Asked Questions
What does AMGEN USA INC do for the federal government?
AMGEN USA INC specializes in the development, manufacturing, and marketing of biologics for the treatment of serious diseases. They provide innovative pharmaceutical products and strong research capabilities to the federal government, supporting the mission of treating and managing serious diseases.
How much taxpayer money does AMGEN USA INC receive?
AMGEN USA INC has received a total of $479.15 billion in government contracts, with an average contract size of $724,886,247. This indicates a significant investment from taxpayers in the company's products and services.
Is AMGEN USA INC good value for taxpayer money?
AMGEN USA INC's sole-source contracts and lack of competitive bidding raise concerns about the transparency and fairness of the contracting process. While the company's innovative products and strong research capabilities are valuable, the lack of competitive bidding could lead to higher costs for taxpayers. The company's contract sizes are substantial, which could be a concern if the contracts are not providing good value for the money.
How does AMGEN USA INC win its contracts?
AMGEN USA INC has not won any new contracts through competitive bidding. All of their contracts are sole-source, indicating a lack of competitive bidding. This suggests that the company is not actively pursuing new opportunities and may be relying on maintaining existing relationships with key agencies.
What agencies use AMGEN USA INC most?
The specific agencies that rely most on AMGEN USA INC are not specified, but their dependency on a few key agencies could pose risks if those agencies reduce their spending or shift to more competitive bidding processes. This concentration of clients could lead to dependency risks and concentration concerns.
What are the risks of relying on AMGEN USA INC?
AMGEN USA INC's sole-source contracts and lack of competitive bidding raise concerns about the transparency and fairness of the contracting process. The company's focus on maintaining existing relationships rather than pursuing new opportunities could limit their growth potential. The concentration of their client base could pose risks if those agencies reduce their spending or shift to more competitive bidding processes.
How does AMGEN USA INC compare to similar contractors?
AMGEN USA INC is a dominant player in the biotechnology sector, known for its innovative pharmaceutical products and strong research capabilities. However, their reliance on sole-source contracts and lack of competitive bidding could be seen as a competitive disadvantage. Compared to industry peers, AMGEN USA INC's focus on maintaining existing relationships rather than pursuing new opportunities could limit their growth potential.
Recent Federal Contracts
Amgen USA Inc has 4 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS awards $774M R&D contract for critical care treatment, with a decade-long... | Department of Health and Human Services | $773.9M | N/A |
| HHS awarded $157M for biological product manufacturing, with a significant po... | Department of Health and Human Services | $157.3M | N/A |
| HHS awards $154M for Colony Stimulating Factors to Amgen USA Inc. to mitigate... | Department of Health and Human Services | $154.4M | N/A |
| HHS awarded $37.7M for Colony Stimulating Factors, a biological product, to A... | Department of Health and Human Services | $37.7M | N/A |